Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) saw some unusual options trading activity on Monday. Traders purchased 4,719 put options on the stock. This is an increase of approximately 355% compared to the typical daily volume of 1,037 put options.
Analyst Ratings Changes
A number of research firms recently weighed in on BDTX. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, September 18th. Piper Sandler restated an “overweight” rating and set a $12.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday, July 3rd. Raymond James began coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $16.00 price objective on shares of Black Diamond Therapeutics in a report on Tuesday, September 10th.
View Our Latest Analysis on Black Diamond Therapeutics
Hedge Funds Weigh In On Black Diamond Therapeutics
Black Diamond Therapeutics Price Performance
Black Diamond Therapeutics stock traded up $0.29 during trading hours on Monday, reaching $5.05. The stock had a trading volume of 24,481,262 shares, compared to its average volume of 778,821. The company has a fifty day simple moving average of $5.69 and a 200-day simple moving average of $5.36. The stock has a market cap of $284.08 million, a PE ratio of -3.10 and a beta of 2.49. Black Diamond Therapeutics has a 52 week low of $1.62 and a 52 week high of $7.66.
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Research analysts predict that Black Diamond Therapeutics will post -1.4 earnings per share for the current fiscal year.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
See Also
- Five stocks we like better than Black Diamond Therapeutics
- Most active stocks: Dollar volume vs share volume
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Industrial Products Stocks Investing
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why eBay Stock Is the Steady Performer You Can’t Ignore
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.